Jazz Pharmaceuticals Public
The 10-second takeaway
For the quarter ended March 31 (Q1), Jazz Pharmaceuticals Public beat expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. Non-GAAP earnings per share grew significantly. GAAP earnings per share expanded significantly.
Margins contracted across the board.
Jazz Pharmaceuticals Public chalked up revenue of $196.2 million. The 10 analysts polled by S&P Capital IQ anticipated revenue of $190.9 million on the same basis. GAAP reported sales were 81% higher than the prior-year quarter's $108.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.37. The 13 earnings estimates compiled by S&P Capital IQ anticipated $1.35 per share. Non-GAAP EPS of $1.37 for Q1 were 51% higher than the prior-year quarter's $0.91 per share. GAAP EPS of $0.71 for Q1 were 48% higher than the prior-year quarter's $0.48 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 86.1%, 620 basis points worse than the prior-year quarter. Operating margin was 34.7%, 370 basis points worse than the prior-year quarter. Net margin was 22.1%, 340 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $204.5 million. On the bottom line, the average EPS estimate is $1.48.
Next year's average estimate for revenue is $830.0 million. The average EPS estimate is $5.96.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 233 members out of 296 rating the stock outperform, and 63 members rating it underperform. Among 73 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 58 give Jazz Pharmaceuticals Public a green thumbs-up, and 15 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Jazz Pharmaceuticals Public is buy, with an average price target of $71.36.
- Add Jazz Pharmaceuticals Public to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.